In January 2022, a policy change expanded Medicaid coverage for continuous glucose monitors (CGMs), creating new opportunities to improve diabetes care for individuals with public insurance. In response, we conducted a study at the Venice Family Clinic, a federally qualified health center in urban Los Angeles, to evaluate the real-world impact of this policy on CGM uptake and glycemic outcomes.

Using patient chart reviews and prospective surveys, we assessed changes in CGM use and identified key barriers to initiating and sustaining CGM use within this community of mostly spanish speaking persons with type 2 diabetes. Our findings aim to inform strategies to expand access, support sustained engagement with CGM technology, and guide policy efforts that promote equitable diabetse care.